Skip to main content

Table 3 Two-way sensitivity analysis: impact of simultaneously varying the QALY adjustment and proportion of BSI represented by Candida on the estimate of cost per QALY of MIC vs. FLU

From: Cost-effectiveness of micafungin as an alternative to fluconazole empiric treatment of suspected ICU-acquired candidemia among patients with sepsis: a model simulation

QALY conversion factor

Candidemia as percentage of all BSI

 

0.048

0.100

0.140

0.200

0.250

0.283

0.44

$50,722

$50,609

$50,522

$50,391

$50,282

$50,210

0.50

$44,636

$44,536

$44,459

$44,344

$44,248

$44,185

0.55

$40,578

$40,487

$40,417

$40,313

$40,226

$40,168

0.60

$37,196

$37,113

$37,049

$36,953

$36,874

$36,821

0.64

$34,872

$34,794

$34,734

$34,644

$34,569

$34,520

0.70

$31,883

$31,811

$31,757

$31,674

$31,606

$31,561

0.75

$29,757

$29,691

$26,639

$29,563

$29,499

$29,457

0.80

$21,897

$27,835

$27,787

$27,715

$27,655

$27,616

  1. BSI = blood stream infection; FLU = fluconazole; MIC = micafungin; QALY = quality-adjusted life year.